Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-7375 in Metastatic KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Phase 2Recruiting
- Sponsor
- Verastem Oncology
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 4
01
Overview
Phase 2, open-label trial of GFH375 in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Verastem Oncology. Primary endpoints: Objective Response Rate at 6 months and Safety and Tolerability at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
GFH375
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07644559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644559.